Neoadjuvant S-1 therapy for resectable pancreatic cancer patients; A phase 2 study
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2019
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 18 Mar 2019 Status changed from active, no longer recruiting to completed.
- 16 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2014 New trial record